Who are Loceryl NL 15 months's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loceryl NL + Cosmetic varnish, Loceryl Nail Lacquer, Amorolfine (Antifungal).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loceryl-nl-15-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Loceryl NL 15 months — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Loceryl NL 15 months (Loceryl NL 15 months) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Morpholine antifungal. Area: Dermatology.

marketed Morpholine antifungal Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Loceryl NL 15 months (Loceryl NL 15 months) — Galderma R&D. Amorolfine is a morpholine antifungal that inhibits fungal sterol synthesis by blocking both Δ14-reductase and Δ8-Δ7-isomerase enzymes in the ergosterol biosynthesis pathway.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Loceryl NL 15 months TARGET	Loceryl NL 15 months	Galderma R&D	marketed	Morpholine antifungal	Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase)
Loceryl NL + Cosmetic varnish	Loceryl NL + Cosmetic varnish	Galderma R&D	marketed	Morpholine antifungal	Δ14-steroid reductase and Δ8→Δ7-isomerase (ergosterol biosynthesis pathway)
Loceryl Nail Lacquer	Loceryl Nail Lacquer	Galderma R&D	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)
Amorolfine (Antifungal)	Amorolfine (Antifungal)	Pierre Fabre Dermo Cosmetique	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Morpholine antifungal class)

Galderma R&D · 3 drugs in this class
Pierre Fabre Dermo Cosmetique · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Loceryl NL 15 months — Competitive Intelligence Brief. https://druglandscape.com/ci/loceryl-nl-15-months. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab